Key statistics
On Wednesday, ACADIA Pharmaceuticals Inc (0A4W:LSE) closed at 26.87, 0.00% below its 52-week high of 26.87, set on Dec 10, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 26.87 |
| Low | 26.87 |
| Bid | -- |
| Offer | -- |
| Previous close | 0.00 |
| Average volume | -- |
|---|---|
| Shares outstanding | 170.49m |
| Free float | 168.23m |
| P/E (TTM) | 10.77 |
| Market cap | 4.19bn USD |
| EPS (TTM) | 2.28 USD |
Data delayed at least 20 minutes, as of Dec 10 2025 14:30 GMT.
More ▼
Press releases
- Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
- Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
- Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
- Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
- Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
- Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
More ▼
